Digestive Health Research
RED-C 3131 Study
This study is currently closed to enrollment.
Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C)
AGE: 18 – 85 years old
SEX AT BIRTH: All
SEX AT BIRTH: All
TYPE: Interventional Drug Study
CONDITION: Liver disease, Hepatic encephalopathy, Cirrhosis
CONDITION: Liver disease, Hepatic encephalopathy, Cirrhosis
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center
LOCATION: UH Cleveland Medical Center
Study Purpose
The purpose of this research study is to see if an investigational drug, Rifaximin SSD-40IR, given twice daily, will help delay the first episode of overt hepatic encephalopathy requiring hospitalization in patients with liver cirrhosis and how safe it is to use in people.
- STUDY20220521